日本护理与医疗相关肺炎的再评价:与社区获得性肺炎的微生物学、耐药及结局比较
作者认为NHCAP可用于描述临床脆弱人群,但不适合作为经验性抗菌治疗决策依据。
要点
- NHCAP组MDR病原体检出率高于CAP(合并OR 3.52,95%CI 2.02-6.14),但分类判别力有限(阳性似然比1.48,阴性似然比0.45)。
- 两组肺炎均近半数未检出病原体,肺炎链球菌均为最常见病原体。
核心结论
- NHCAP可识别临床脆弱人群,但预测耐药病原体的效用有限,支持其作为描述性临床框架而非经验性抗菌治疗决策依据。
主要发现
- NHCAP患者较CAP患者年龄更大且合并症负担更高。
- NHCAP与CAP组未检出病原体的合并比例分别为0.48和0.46。
- 肺炎链球菌在两组中均为最常检出病原体。
- NHCAP组MDR病原体检出率高于CAP,合并OR 3.52(95%CI 2.02-6.14)。
关键数值与推荐
- NHCAP分类对MDR病原体的合并阳性似然比为1.48,阴性似然比为0.45,对验后概率影响很小。
临床怎么用
- 可将NHCAP用于识别高龄、合并症多、死亡风险较高的肺炎患者,但不宜仅凭NHCAP分类决定经验性抗菌治疗。
局限性
- 纳入研究均为日本观察性研究,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respir Investig. 2026 Sep;64(5):101480. doi: 10.1016/j.resinv.2026.101480. Epub 2026 Jul 10. ABSTRACT BACKGROUND: In Japan, nursing- and healthcare-associated pneumonia (NHCAP) is used to describe pneumonia in patients with substantial exposure to healthcare and nursing care services. A systematic review and meta-analysis was conducted to re-evaluate their clinical significance. METHODS: Thirteen observational studies conducted in Japan directly comparing NHCAP with community-acquired pneumonia (CAP) were included. RESULTS: Patients with NHCAP were consistently older and had a higher burden of comorbidities than those with CAP. Thirty-day mortality was significantly higher in the NHCAP group than in the CAP group (12.7% vs. 5.0%), with a pooled odds ratio of 2.85 (95% confidence interval [CI], 2.25-3.61). In both groups, nearly half of the pneumonia cases had no identified etiological pathogen, with pooled proportions of 0.48 and 0.46 in the NHCAP and CAP groups, respectively. Streptococcus pneumoniae was the most frequently detected pathogen in both groups, and multidrug-resistant (MDR) pathogens were detected more frequently in NHCAP than in CAP (pooled odds ratio, 3.52; 95% CI, 2.02-6.14). However, despite this higher prevalence, the NHCAP classification showed limited discriminatory performance for MDR pathogens, with a pooled positive likelihood ratio of 1.48 and a negative likelihood ratio of 0.45, indicating a minimal impact on post-test probability. CONCLUSIONS: NHCAP identifies a clinically vulnerable population but has limited utility in predicting drug-resistant pathogens, supporting its use as a descriptive clinical framework rather than that used to determine empirical antimicrobial therapy. PMID: 42431010 | DOI: 10.1016/j.resinv.2026.101480
引用
- PubMed 高证据 · 肺炎:Revisiting nursing- and healthcare-associated pneumonia in Japan: Microbiology, multidrug resistance, and clinical outcomes compared with community-acquired pneumonia
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。